Participants
DISEASE, COVID-19 INFECTION
Eligible cases were adult patients admitted to our institution due to COVID-19 infection. They must have presented with mild disease (defined as grade 3 or 4 in the WHO-Ordinal Scale for Clinical Improvement [WHO-OSCI]) and provided consent (The study was performed at the Hospital Universitario Sanchinarro, Madrid (Spain).Treatment in the control arm consisted of standard of care (SOC), including corticosteroids, tocilizumab, heparin and any other therapy considered appropriate by clinical investigators.The experimental arm consisted of SOC plus the combination of ruxolitinib 5 mg twice a day for 7 days followed by 10 mg BID for 7 days plus Simvastatin 40 mg once a day for 14 days.Early dose scalation and higher doses of ruxolitinib were permitted on physicians’ discretion. Crossover to the ruxolitinib arm was allowed and continuation of treatment beyond 14 days was also permitted if patients were considered to obtain clinical benefit by the treating physicians.Patients taking statins before hospital admission, continued with the original medication. Those assigned to the experimental arm received ruxolitinib as referred.